ArticleScientific reports2017
Perfluorooctane sulfonate affects intestinal immunity against bacterial infection.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 38 citations in OpenAlex.
- Investigation of the Effects of Perfluorooctane Sulfonic Acid (PFOS) and Perfluorooctanoic Acid (PFOA) Exposure on Interleukin-17 Signalling and Poly(I:C)-Induced Lung Inflammation in BALB/c Mice.Basic & clinical pharmacology & toxicology · 2026Article
- Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review.Current issues in molecular biology · 2025Review
- Immune cell profiles associated with human exposure to perfluorinated compounds (PFAS) suggest changes in natural killer, T helper, and T cytotoxic cell subpopulations.Environmental research · 2024Article
- Consideration of pathways for immunotoxicity of per- and polyfluoroalkyl substances (PFAS).Environmental health : a global access science source · 2023Review
- ILC3: a case of conflicted identity.Frontiers in immunology · 2023Review
- Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: A nested case control analysis in the Nurses' Health Study cohorts.Environmental research · 2022Article
- Perfluorooctanesulfonic acid modulates barrier function and systemic T-cell homeostasis during intestinal inflammation.Disease models & mechanisms · 2021Article
- Temporal and Geographical Variation of Intestinal Ulcers in Grey Seals (Animals : an open access journal from MDPI · 2021Article
- Inactivation of common airborne antigens by perfluoroalkyl chemicals modulates early life allergic asthma.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Effect of Perfluorooctanesulfonic acid (PFOS) on immune cell development and function in mice.Immunology letters · 2021Article
- Perfluorooctane sulfonate exerts inflammatory bowel disease-like intestinal injury in rats.PeerJ · 2021Article
- Risk to human health related to the presence of perfluoroalkyl substances in food.EFSA journal. European Food Safety Authority · 2020Article
- Mucus: An Underestimated Gut Target for Environmental Pollutants and Food Additives.Microorganisms · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Perfluorooctane sulfonate (PFOS) is an environmental contaminant that has been manufactured to be used as surfactants and repellents in industry. Due to long half-life for clearance and degradation, PFOS is accumulative in human body and has potential threat to human health. Previous studies have shown the development and function of immune cells can be affected by PFOS. Although PFOS has a high chance of being absorbed through the oral route, whether and how PFOS affects immune cells in the gut is unknown. Using mouse model of Citrobacter rodentium infection, we investigated the role of PFOS on intestinal immunity. We found at early phase of the infection, PFOS inhibited the expansion of the pathogen by promoting IL-22 production from the group 3 innate lymphoid cell (ILC3) in an aryl hydrocarbon receptor dependent manner. Nevertheless, persistent PFOS treatment in mice finally led to a failure to clear the pathogen completely. At late phase of infection, enhanced bacterial counts in PFOS treated mice were accompanied by increased inflammatory cytokines, reduced mucin production and dysbiosis, featured by decreased level of Lactobacillus casei, Lactobacillus johnsonii and increased E. coli. Our study reveals a deleterious consequence in intestinal bacterial infection caused by PFOS accumulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.